₹70
▲ +0.64 +0.92%
17 Jul 2026
NSE Listed · Pharmaceuticals
ESM 1Lyka Labs Ltd. (LYKALABS)
Volume: 6,009Avg Vol 1W: 2,927Avg Vol 1M: 7,63952W Range:₹44.1₹121.44
Key Ratios
Checked just nowMarket Cap₹251 Cr
Current Price₹70
Previous Close₹69.36
High / Low (52w)₹121.44 / ₹44.1
Volume6,009
Avg Vol (1W)2,927
Avg Vol (1M)7,639
Stock P/E45.07
Book Value₹25.68
Dividend Yield0%
ROE-10.86%
ROA-5.98%
Revenue (TTM)—
Revenue Growth24.55%
Profit Margin-7.82%
Total Debt₹18 Cr
Shares Outstanding4 Cr
Face Value₹10
EPS (TTM)₹0
P/B2.7
Debt / Equity0.55
50 DMA₹70.51
200 DMA₹61.84
Day change+0.92%
SurveillanceESM 1 (as of 2026-07-17)
Price Chart
₹70▼ 17.04% · 1Y
2025-11-212026-07-16
20-day avg volume: 7K shares
Pros
- Company is almost debt-free.
- Revenue grew 25% YoY.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹30 Cr | ₹41 Cr | ₹34 Cr | ₹33 Cr | ₹33 Cr | ₹37 Cr | ₹31 Cr | ₹28 Cr |
| EBITDA | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹-4 Cr | ₹1 Cr | ₹-8 Cr |
| Net Profit | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹-3 Cr | ₹0 Cr | ₹-8 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹62 Cr | ₹73 Cr | ₹65 Cr | ₹88 Cr | ₹196 Cr | ₹96 Cr | ₹113 Cr | ₹141 Cr |
| EBITDA | ₹-13 Cr | ₹-7 Cr | ₹-9 Cr | ₹13 Cr | ₹86 Cr | ₹6 Cr | ₹4 Cr | ₹13 Cr |
| Net Profit | ₹-17 Cr | ₹-6 Cr | ₹-61 Cr | ₹-12 Cr | ₹39 Cr | ₹-13 Cr | ₹-3 Cr | ₹8 Cr |
| EPS | -6.69 | -1.97 | -21.29 | -4.03 | 13.59 | -4.63 | -0.79 | 2.22 |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹229 Cr | ₹216 Cr | ₹200 Cr | ₹190 Cr | ₹186 Cr | ₹152 Cr | ₹157 Cr | ₹176 Cr |
| Total Liabilities | ₹176 Cr | ₹170 Cr | ₹215 Cr | ₹215 Cr | ₹172 Cr | ₹106 Cr | ₹88 Cr | ₹73 Cr |
| Equity | ₹53 Cr | ₹46 Cr | ₹-15 Cr | ₹-25 Cr | ₹13 Cr | ₹46 Cr | ₹68 Cr | ₹104 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹11 Cr | ₹27 Cr | ₹5 Cr | ₹10 Cr | ₹80 Cr | ₹9 Cr | ₹3 Cr | ₹5 Cr |
| Investing | ₹-3 Cr | ₹-4 Cr | ₹0 Cr | ₹0 Cr | ₹-6 Cr | ₹7 Cr | ₹-9 Cr | ₹-12 Cr |
| Financing | ₹-10 Cr | ₹-23 Cr | ₹3 Cr | ₹-12 Cr | ₹-63 Cr | ₹-22 Cr | ₹2 Cr | ₹5 Cr |
| Free Cash Flow | ₹11 Cr | ₹27 Cr | ₹5 Cr | ₹10 Cr | ₹80 Cr | ₹9 Cr | ₹3 Cr | ₹5 Cr |
Shareholding
Promoter 58.16% Institutions 0.95% Public 40.88%
Efficiency & Working Capital
ROCE-6%
Interest Coverage5.9
Dividend Payout—
Debtor Days114 d
Inventory Days33 d
Payable Days39 d
Cash Conversion Cycle107 d
Working Capital Days146 d
Shareholding Details
As of 2026-03-31
Promoter58.2%
FII0.3%
DII0.7%
Institutions1%
Public40.9%
Promoter Pledge0%
No. of Shareholders26,727
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Dec 2023 | Mar 2024 | Apr 2024 | Apr 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 54.8% | 54.8% | 58.1% | 58.1% | 58.1% | 58.1% | 58.1% | 58.2% | 58.2% | 58.2% | 58.2% | 58.2% |
| FIIs | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.3% |
| DIIs | 0.4% | 0.9% | 0.8% | 0.8% | 0.8% | 0.7% | 0.7% | 0.7% | 0.7% | 0.7% | 0.7% | 0.7% |
| Public | 44.6% | 44.1% | 40.9% | 40.9% | 41% | 41.1% | 41.1% | 40.9% | 41% | 41% | 41% | 40.9% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 26,422 | 25,717 | 25,699 | 25,699 | 25,716 | 28,943 | 29,099 | 28,472 | 28,189 | 27,743 | 27,155 | 26,727 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Ipca Laboratories Limited | Shareholding of Promoter and Promoter Group | 41% | 1.46 Cr |
| Kunal Narendra Gandhi | Shareholding of Promoter and Promoter Group | 9.8% | 34,93,629 |
| Nehal Narendra Gandhi | Shareholding of Promoter and Promoter Group | 3.3% | 11,62,371 |
| Enai Trading And Investment Pvt. Ltd | Shareholding of Promoter and Promoter Group | 2.8% | 10,00,000 |
| Thermo Capital Private Limited | Public Shareholding | 2% | 7,11,618 |
| Pranay Godha | Shareholding of Promoter and Promoter Group | 0.8% | 3,00,000 |
| Alisha Kunal Gandhi | Shareholding of Promoter and Promoter Group | 0.1% | 45,000 |
| Sweta Shah | Shareholding of Promoter and Promoter Group | 0.1% | 41,000 |
| Ushma Ronak Shah | Shareholding of Promoter and Promoter Group | 0.1% | 33,000 |
| Lyka Generics Limited | Shareholding of Promoter and Promoter Group | 0.1% | 20,000 |
| Neetu Godha | Shareholding of Promoter and Promoter Group | 0% | 10,000 |
| Usha Godha | Shareholding of Promoter and Promoter Group | 0% | 10,686 |
| Premchand Godha | Shareholding of Promoter and Promoter Group | 0% | 10,900 |
| Bhawna Godha | Shareholding of Promoter and Promoter Group | 0% | 6,000 |
| Hiralaxmi Multitrade Private Limited | Shareholding of Promoter and Promoter Group | 0% | 708 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Bhawna Godha | 0 | 0% | 2026-03-31 |
| Neetu Godha | 0 | 0% | 2026-03-31 |
| Usha Godha | 0 | 0% | 2026-03-31 |
| Premchand Godha | 0 | 0% | 2026-03-31 |
| Ushma Ronak Shah | 0 | 0% | 2026-03-31 |
| Sweta Shah | 0 | 0% | 2026-03-31 |
| Alisha Kunal Gandhi | 0 | 0% | 2026-03-31 |
| Pranay Godha | 0 | 0% | 2026-03-31 |
| Nehal Narendra Gandhi | 0 | 0% | 2026-03-31 |
| Kunal Narendra Gandhi | 0 | 0% | 2026-03-31 |
| Hiralaxmi Multitrade Private Limited | 0 | 0% | 2026-03-31 |
| Lyka Generics Limited | 0 | 0% | 2026-03-31 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| KUNAL NARENDRA GANDHI | Managing Director & Chief Executive Officer | 2025 |
| Yogesh B Shah | Whole Time Director & Chief Financial Officer | 2025 |
| Dhara P. Shah | Non Executive & Independent Director | 2025 |
| Babulal Jain | Chairman & Independent Director | 2025 |
| Prashant Godha | Non Executive Director | 2025 |
| Shashil Mendonsa | Non Executive Director | 2025 |
| Archana Yadav | Non Executive & Independent Director | 2025 |
| Neeraj Golas | Non Executive & Independent Director | 2025 |
| Shailendra Kumar Agrawal | Company Sec. & Compli. Officer | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceutical products/Pharma rela | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| Domestic | ₹85 Cr | 65.4% |
| Exports | ₹45 Cr | 34.6% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 48 | 36 | 36 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 5 | 0 | 0 | 9 | 10 | 138 |
| 2025 | 3 | 0 | 0 | 0 | 9 | 60 |
| 2025 | 0 | 0 | 0 | 0 | 1 | 1 |
Insider / Designated-Person Trades
30 recent disclosure(s)
Kunal N GandhiAcquisition · 1,262
Kunal N GandhiAcquisition · 12,914
Kunal N GandhiAcquisition · 1,262
Kunal N GandhiAcquisition · 12,914
Enai Trading and Investment Pvt.Acquisition · 11,312
Alisha GandhiAcquisition · 5,000
Substantial Acquisitions (SAST)
8 disclosure(s)
Inter-se Transfer25/06/2025 · 74,000
Inter-se Transfer25/06/2025 · 74,000
Inter-se Transfer24/03/2025 · 10,68,629
Conv. of Warrants16/04/2024 · 26,00,000
Market22/09/2023 · 24,839
Market22/09/2023 · 24,839
Company Information
Incorporated1976
ChairmanBabulal Jain
AuditorD Kothary & Co
Investor Email[email protected]; [email protected]
📍 4801/B & 4802/A, GIDC Industrial Estate, Ankleshwar, Gujarat, 393002
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search